8:00 am Registration & Networking Coffee

8:50 am Chair’s Opening Remarks

Assessing Current Limitations of Cell Engagers including Strategies to Mitigate Toxicities to Ensure Patient Safety

9:00 am XTENylated Protease Activated T Cell Engagers: XPATS – A Novel Format to Mitigate the On-target, Off-tumor Problem

9:30 am T Cell Engaging Antibody Circuits (TEAC): Focusing Immune Activation to the Cancer Cell Surface to Widen the Therapeutic Index

10:00 am TriTACs Are T Cell Engaging Drugs for Treatment of Solid Tumors

  • Rick Austin Senior Director of Biology Research, Harpoon

10:30 am Speed Networking & Morning Refreshments

12:00 pm Panel Discussion: Exploiting the High Protease Concentration in the Tumor Microenvironment to Reduce Toxicity

12:45 pm Networking Lunch

Improving the Therapeutic Window of Cell Engagers: Addressing Half-Life and Cytokine Release Syndrome

2:00 pm Discovering and Designing the Next Generation of T cell Engagers

2:30 pm Optimizing Therapeutic Index and Other Properties with Potency Reduction and Bivalent Target Engagement

3:00 pm CB307: A Novel T cell Enhancing Humabody Bispecific

3:00 pm


  • T Cell Engagers with poor manufacturability can be improved using engineered coli SoluPro® cell linesT Cell Engagers with poor manufacturability can be improved using engineered coli SoluPro® cell lines
  • A novel synthetic biology strategy using coli SoluPro® enables rapid and soluble expression of T Cell Engager proteins
  • Precise engineering of protein expression conditions, folding solutions, and cytoplasmic conditions enable optimization of parameters for production of high titer, high quality therapeutics

3:30 pm Afternoon Refreshments & Networking

Review of Current Clinical Data

4:00 pm Translating Preclinical BiTE® Data to the Clinic

4:30 pm Flotetuzumab: An Experimental CD123 x CD3 Bispecific DART Molecule for the Treatment of AML

  • Jan Davidson Director of Clinical Development & Research , Macrogenics

5:00 pm AMV564 Relieves Immune Suppression Through Selective Targeting of CD33

5:30 pm Chair’s Closing Remarks & End of Day One